Linked Data API

Show Search Form

Search Results

1027714
registered interest false more like this
date less than 2018-12-18more like thismore than 2018-12-18
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Drugs remove filter
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, pursuant to the Answer on 11 September to Question number 169109 on Social Care: Drugs, (a) when the 2019-20 planning process was completed and (b) what the level of funding is for the 2019-20 prioritisation process. more like this
tabling member constituency Alyn and Deeside more like this
tabling member printed
Mark Tami more like this
uin 203288 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2018-12-20more like thismore than 2018-12-20
answer text <p>The independently chaired Clinical Priorities Advisory Group met in November 2018 to make prioritisation recommendations for investments in specialised service for the 2019/20 financial year. Final investment decisions will be announced shortly. A second prioritisation round for investment in 2019/20 will be held next year.</p><p> </p><p>The baseline budget for prioritisation in 2019/20 has been set at £25.7 million reflecting a 2.7% increase on the 2018/19 budget. The availability of any additional funding to support prioritisation will be kept under review between now and May/June 2019 when the second round of investment decisions will be taken for the 2019/20 financial year.</p> more like this
answering member constituency Winchester more like this
answering member printed Steve Brine more like this
question first answered
less than 2018-12-20T15:58:15.86Zmore like thismore than 2018-12-20T15:58:15.86Z
answering member
4067
label Biography information for Steve Brine more like this
tabling member
1383
label Biography information for Mark Tami more like this
1010643
registered interest false more like this
date less than 2018-11-20more like thismore than 2018-11-20
answering body
Department for Business, Energy and Industrial Strategy more like this
answering dept id 201 more like this
answering dept short name Business, Energy and Industrial Strategy more like this
answering dept sort name Business, Energy and Industrial Strategy more like this
hansard heading Drugs remove filter
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Business, Energy and Industrial Strategy, what his assessment is of the potential costs to the pharmaceutical industry of Article 45 of the Draft Agreement on the withdrawal of the United Kingdom of Great Britain and Northern Ireland from the European Union and the European Atomic Energy Community. more like this
tabling member constituency Bishop Auckland more like this
tabling member printed
Helen Goodman more like this
uin 193398 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2018-11-28more like thismore than 2018-11-28
answer text <p>There will be no cost to the pharmaceutical industry as a result of Article 45 of the draft Withdrawal Agreement. The Article requires the UK to share marketing authorisation data with the European Medicines Agency or Member States where needed for assessing generic marketing applications when requested. Member States will also be required to provide the UK with the same information when requested. The UK’s Medicines and Healthcare Products Regulatory Agency already regularly shares and receives such data with the European Medicines Agency and other Member States.</p> more like this
answering member constituency Rochester and Strood more like this
answering member printed Kelly Tolhurst more like this
question first answered
less than 2018-11-28T11:39:03.407Zmore like thismore than 2018-11-28T11:39:03.407Z
answering member
4487
label Biography information for Kelly Tolhurst more like this
tabling member
1484
label Biography information for Helen Goodman more like this
986430
registered interest false more like this
date less than 2018-10-12more like thismore than 2018-10-12
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Drugs remove filter
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, with reference to the consultation undertaken by NICE on charging for technology appraisal and highly specialised technology, (a) how many and (b) what proportion of responses were (i) supportive of and (ii) opposed to the proposals; and if he will make a statement. more like this
tabling member constituency Newton Abbot more like this
tabling member printed
Anne Marie Morris more like this
uin 178509 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2018-10-17more like thismore than 2018-10-17
answer text <p>The Government recently consulted on draft amendments to regulations that would enable the National Institute for Health and Care Excellence (NICE) to charge companies for the cost of developing technology appraisal and highly specialised technology evaluation recommendations relating to their products, as well as to allow NICE to recruit appeal panel members representing the National Health Service from the devolved administrations. 78 organisations and individuals responded to the consultation. The Government is currently analysing the responses and will publish its response in due course.</p> more like this
answering member constituency Winchester more like this
answering member printed Steve Brine more like this
question first answered
less than 2018-10-17T16:36:20.397Zmore like thismore than 2018-10-17T16:36:20.397Z
answering member
4067
label Biography information for Steve Brine more like this
tabling member
4249
label Biography information for Anne Marie Morris more like this
983301
registered interest false more like this
date less than 2018-10-08more like thismore than 2018-10-08
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Drugs remove filter
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 10 September 2018 to Question 170317, on Drugs, what estimate he has made of the number of weeks delay for medicines there will be at the UK border in the event that the UK leaves the EU without a deal; and whether that estimate has been revised since his letter of 23 August 2018 to the pharmaceutical industry. more like this
tabling member constituency Darlington more like this
tabling member printed
Jenny Chapman more like this
uin 176238 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2018-10-11more like thismore than 2018-10-11
answer text <p>Our request to suppliers is for them to store an additional six weeks’ stock. This will be on top of their business as usual contingency stockpiles. Six weeks is the current cross-Government planning assumption but will of course be subject to revision in light of future developments.</p> more like this
answering member constituency North East Cambridgeshire more like this
answering member printed Stephen Barclay more like this
question first answered
less than 2018-10-11T15:58:35.717Zmore like thismore than 2018-10-11T15:58:35.717Z
answering member
4095
label Biography information for Stephen Barclay more like this
tabling member
3972
label Biography information for Jenny Chapman more like this
971761
registered interest false more like this
date less than 2018-09-11more like thismore than 2018-09-11
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Drugs remove filter
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what estimate he has made of the money that would be accrued to the public purse of the introduction of charges by NICE for companies whose products are selected for technology appraisal. more like this
tabling member constituency Newton Abbot more like this
tabling member printed
Anne Marie Morris more like this
uin 173639 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2018-10-09more like thismore than 2018-10-09
answer text <p>The Department published a consultation on 10 August titled ‘NICE's technology appraisal and highly specialised technology work programmes – Charging and Appeal Panels’ which ran until 14 September 2018.</p><p> </p><p>Prior to the consultation, the Department and the National Institute of Health and Care Excellence (NICE) considered a number of options as well as charging. These are described in the consultation document and Impact Assessment which are published at the following link:</p><p> </p><p><a href="https://www.gov.uk/government/consultations/nice-recommendations-charging-and-appeal-panels" target="_blank">https://www.gov.uk/government/consultations/nice-recommendations-charging-and-appeal-panels</a></p><p> </p><p>The document also explains that based on current activity levels and the proposed charges, NICE expects it would generate £10 million per annum from charging and that, should charges be introduced, they would be reviewed after years one and two and periodically thereafter to ensure that there is no detrimental impact on the willingness of companies, including small companies, to launch products in the United Kingdom.</p><p> </p><p>The Government will carefully consider comments received in response to the consultation and will publish its response in due course.</p>
answering member constituency Winchester more like this
answering member printed Steve Brine more like this
grouped question UIN
173640 more like this
173641 more like this
question first answered
less than 2018-10-09T17:00:54.877Zmore like thismore than 2018-10-09T17:00:54.877Z
answering member
4067
label Biography information for Steve Brine more like this
tabling member
4249
label Biography information for Anne Marie Morris more like this
971762
registered interest false more like this
date less than 2018-09-11more like thismore than 2018-09-11
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Drugs remove filter
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what estimate he has made of the cost to the public purse in foregone (a) tax and (b) other revenues in the event that NICE introduces charges for technology appraisals and companies choose not to launch products in England. more like this
tabling member constituency Newton Abbot more like this
tabling member printed
Anne Marie Morris more like this
uin 173640 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2018-10-09more like thismore than 2018-10-09
answer text <p>The Department published a consultation on 10 August titled ‘NICE's technology appraisal and highly specialised technology work programmes – Charging and Appeal Panels’ which ran until 14 September 2018.</p><p> </p><p>Prior to the consultation, the Department and the National Institute of Health and Care Excellence (NICE) considered a number of options as well as charging. These are described in the consultation document and Impact Assessment which are published at the following link:</p><p> </p><p><a href="https://www.gov.uk/government/consultations/nice-recommendations-charging-and-appeal-panels" target="_blank">https://www.gov.uk/government/consultations/nice-recommendations-charging-and-appeal-panels</a></p><p> </p><p>The document also explains that based on current activity levels and the proposed charges, NICE expects it would generate £10 million per annum from charging and that, should charges be introduced, they would be reviewed after years one and two and periodically thereafter to ensure that there is no detrimental impact on the willingness of companies, including small companies, to launch products in the United Kingdom.</p><p> </p><p>The Government will carefully consider comments received in response to the consultation and will publish its response in due course.</p>
answering member constituency Winchester more like this
answering member printed Steve Brine more like this
grouped question UIN
173639 more like this
173641 more like this
question first answered
less than 2018-10-09T17:00:54.94Zmore like thismore than 2018-10-09T17:00:54.94Z
answering member
4067
label Biography information for Steve Brine more like this
tabling member
4249
label Biography information for Anne Marie Morris more like this
971763
registered interest false more like this
date less than 2018-09-11more like thismore than 2018-09-11
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Drugs remove filter
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, whether he has made an assessment of the potential effectiveness of options available to NICE other than charging for technology appraisals to tackle changes in the level of its central Government funding; and if he will make a statement. more like this
tabling member constituency Newton Abbot more like this
tabling member printed
Anne Marie Morris more like this
uin 173641 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2018-10-09more like thismore than 2018-10-09
answer text <p>The Department published a consultation on 10 August titled ‘NICE's technology appraisal and highly specialised technology work programmes – Charging and Appeal Panels’ which ran until 14 September 2018.</p><p> </p><p>Prior to the consultation, the Department and the National Institute of Health and Care Excellence (NICE) considered a number of options as well as charging. These are described in the consultation document and Impact Assessment which are published at the following link:</p><p> </p><p><a href="https://www.gov.uk/government/consultations/nice-recommendations-charging-and-appeal-panels" target="_blank">https://www.gov.uk/government/consultations/nice-recommendations-charging-and-appeal-panels</a></p><p> </p><p>The document also explains that based on current activity levels and the proposed charges, NICE expects it would generate £10 million per annum from charging and that, should charges be introduced, they would be reviewed after years one and two and periodically thereafter to ensure that there is no detrimental impact on the willingness of companies, including small companies, to launch products in the United Kingdom.</p><p> </p><p>The Government will carefully consider comments received in response to the consultation and will publish its response in due course.</p>
answering member constituency Winchester more like this
answering member printed Steve Brine more like this
grouped question UIN
173639 more like this
173640 more like this
question first answered
less than 2018-10-09T17:00:54.987Zmore like thismore than 2018-10-09T17:00:54.987Z
answering member
4067
label Biography information for Steve Brine more like this
tabling member
4249
label Biography information for Anne Marie Morris more like this
971888
registered interest false more like this
date less than 2018-09-11more like thismore than 2018-09-11
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Drugs remove filter
house id 2 more like this
legislature
25277
pref label House of Lords more like this
question text To ask Her Majesty's Government what recent discussions they have had with the devolved administrations regarding the supply of medicine to the devolved nations in the event of a no-deal Brexit. more like this
tabling member printed
Baroness Jolly more like this
uin HL10251 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2018-09-20more like thismore than 2018-09-20
answer text <p>On 23 August 2018 the Department published an open letter online to all pharmaceutical companies asking them to ensure that United Kingdom stockpiles of medicines are appropriate to cope with potential delays at the border that may arise in the event of a no-deal Brexit. A copy of the letter is attached.</p><p>At the same time the Department also wrote to pharmaceutical companies that supply the UK with prescription-only-medicines and pharmacy medicines from, or via, the European Union/European Economic Area (EEA), asking them to ensure they have a minimum of six weeks’ additional supply in the UK, over and above their business as usual operational buffer stocks, by 29 March 2019. The Department also asked those suppliers to indicate how they propose to ensure continuity of supply of their products to the National Health Service as part of the Department’s contingency programme. We are unable to provide the names of these companies as this information is commercially sensitive.</p><p>General sales list (over-the-counter) medicines were not included in the Department’s request to suppliers to indicate their contingency plans to us, and therefore are not currently formally part of our contingency programme. We have, however, encouraged all medicines suppliers to the UK with a EU/EEA touchpoint to stockpile or make alternative arrangements and are confident that this is the best approach to ensure supply at pharmacies and retail outlets in the event of a no-deal Brexit.</p><p>The Department also wrote to hospitals, general practitioners and community pharmacies informing them that they do not need to take any steps to stockpile additional medicines, beyond their business as usual stock levels, as this is not necessary due to our contingency plans in partnership with pharmaceutical companies.</p><p>We are not currently aware of any healthcare providers or other health care organisations acquiring medicines in volumes that would qualify as stockpiling but we will work with NHS colleagues to closely monitor and follow up any incidences of over ordering of medicines.</p><p>The Department has worked collaboratively with the devolved administrations to ensure a UK-wide approach to our contingency plans which includes the supply of medicines to the devolved nations. Officials from the devolved administrations are members of a cross-Government working group and were informed of our 23 August announcements in advance.</p>
answering member printed Lord O'Shaughnessy more like this
grouped question UIN
HL10252 more like this
HL10253 more like this
HL10254 more like this
HL10255 more like this
question first answered
less than 2018-09-20T14:11:14.263Zmore like thismore than 2018-09-20T14:11:14.263Z
answering member
4545
label Biography information for Lord O'Shaughnessy more like this
attachment
1
file name Brexit - Medicines letter.pdf more like this
title Letter to pharmaceutical companies more like this
tabling member
4203
label Biography information for Baroness Jolly more like this
971890
registered interest false more like this
date less than 2018-09-11more like thismore than 2018-09-11
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Drugs remove filter
house id 2 more like this
legislature
25277
pref label House of Lords more like this
question text To ask Her Majesty's Government which pharmaceutical companies, if any, they have been working with to ensure that UK stockpiles of medicines are adequate to cope with a no-deal Brexit. more like this
tabling member printed
Baroness Jolly more like this
uin HL10252 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2018-09-20more like thismore than 2018-09-20
answer text <p>On 23 August 2018 the Department published an open letter online to all pharmaceutical companies asking them to ensure that United Kingdom stockpiles of medicines are appropriate to cope with potential delays at the border that may arise in the event of a no-deal Brexit. A copy of the letter is attached.</p><p>At the same time the Department also wrote to pharmaceutical companies that supply the UK with prescription-only-medicines and pharmacy medicines from, or via, the European Union/European Economic Area (EEA), asking them to ensure they have a minimum of six weeks’ additional supply in the UK, over and above their business as usual operational buffer stocks, by 29 March 2019. The Department also asked those suppliers to indicate how they propose to ensure continuity of supply of their products to the National Health Service as part of the Department’s contingency programme. We are unable to provide the names of these companies as this information is commercially sensitive.</p><p>General sales list (over-the-counter) medicines were not included in the Department’s request to suppliers to indicate their contingency plans to us, and therefore are not currently formally part of our contingency programme. We have, however, encouraged all medicines suppliers to the UK with a EU/EEA touchpoint to stockpile or make alternative arrangements and are confident that this is the best approach to ensure supply at pharmacies and retail outlets in the event of a no-deal Brexit.</p><p>The Department also wrote to hospitals, general practitioners and community pharmacies informing them that they do not need to take any steps to stockpile additional medicines, beyond their business as usual stock levels, as this is not necessary due to our contingency plans in partnership with pharmaceutical companies.</p><p>We are not currently aware of any healthcare providers or other health care organisations acquiring medicines in volumes that would qualify as stockpiling but we will work with NHS colleagues to closely monitor and follow up any incidences of over ordering of medicines.</p><p>The Department has worked collaboratively with the devolved administrations to ensure a UK-wide approach to our contingency plans which includes the supply of medicines to the devolved nations. Officials from the devolved administrations are members of a cross-Government working group and were informed of our 23 August announcements in advance.</p>
answering member printed Lord O'Shaughnessy more like this
grouped question UIN
HL10251 more like this
HL10253 more like this
HL10254 more like this
HL10255 more like this
question first answered
less than 2018-09-20T14:11:14.34Zmore like thismore than 2018-09-20T14:11:14.34Z
answering member
4545
label Biography information for Lord O'Shaughnessy more like this
attachment
1
file name Brexit - Medicines letter.pdf more like this
title Letter to pharmaceutical companies more like this
tabling member
4203
label Biography information for Baroness Jolly more like this
971891
registered interest false more like this
date less than 2018-09-11more like thismore than 2018-09-11
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Drugs remove filter
house id 2 more like this
legislature
25277
pref label House of Lords more like this
question text To ask Her Majesty's Government whether any health organisations in the UK, other than pharmaceutical companies, are stockpiling medicines in preparation for a no-deal Brexit. more like this
tabling member printed
Baroness Jolly more like this
uin HL10253 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2018-09-20more like thismore than 2018-09-20
answer text <p>On 23 August 2018 the Department published an open letter online to all pharmaceutical companies asking them to ensure that United Kingdom stockpiles of medicines are appropriate to cope with potential delays at the border that may arise in the event of a no-deal Brexit. A copy of the letter is attached.</p><p>At the same time the Department also wrote to pharmaceutical companies that supply the UK with prescription-only-medicines and pharmacy medicines from, or via, the European Union/European Economic Area (EEA), asking them to ensure they have a minimum of six weeks’ additional supply in the UK, over and above their business as usual operational buffer stocks, by 29 March 2019. The Department also asked those suppliers to indicate how they propose to ensure continuity of supply of their products to the National Health Service as part of the Department’s contingency programme. We are unable to provide the names of these companies as this information is commercially sensitive.</p><p>General sales list (over-the-counter) medicines were not included in the Department’s request to suppliers to indicate their contingency plans to us, and therefore are not currently formally part of our contingency programme. We have, however, encouraged all medicines suppliers to the UK with a EU/EEA touchpoint to stockpile or make alternative arrangements and are confident that this is the best approach to ensure supply at pharmacies and retail outlets in the event of a no-deal Brexit.</p><p>The Department also wrote to hospitals, general practitioners and community pharmacies informing them that they do not need to take any steps to stockpile additional medicines, beyond their business as usual stock levels, as this is not necessary due to our contingency plans in partnership with pharmaceutical companies.</p><p>We are not currently aware of any healthcare providers or other health care organisations acquiring medicines in volumes that would qualify as stockpiling but we will work with NHS colleagues to closely monitor and follow up any incidences of over ordering of medicines.</p><p>The Department has worked collaboratively with the devolved administrations to ensure a UK-wide approach to our contingency plans which includes the supply of medicines to the devolved nations. Officials from the devolved administrations are members of a cross-Government working group and were informed of our 23 August announcements in advance.</p>
answering member printed Lord O'Shaughnessy more like this
grouped question UIN
HL10251 more like this
HL10252 more like this
HL10254 more like this
HL10255 more like this
question first answered
less than 2018-09-20T14:11:14.403Zmore like thismore than 2018-09-20T14:11:14.403Z
answering member
4545
label Biography information for Lord O'Shaughnessy more like this
attachment
1
file name Brexit - Medicines letter.pdf more like this
title Letter to pharmaceutical companies more like this
tabling member
4203
label Biography information for Baroness Jolly more like this